Big Russian Pharma
AstraZeneca invests more than $ 150 million in the construction of a pharmaceutical plant in Russia
RIA News
Swedish-British biopharmaceutical giant AstraZeneca intends to invest more than $ 150 million in the construction of a plant in Russia with a capacity of 16 million packages per year, the company said in a statement. Full-cycle production, from the preparation of dosage forms to packaging, will be located in the Kaluga Region on the territory of the Vorsino Industrial Park. The start of construction work is scheduled for April 2011, and the release of the first finished products is scheduled for spring 2013. According to the company's plans, up to 145 employees will be involved in the enterprise.
The plant will produce drugs aimed at the treatment of socially significant diseases, such as oncological, cardiological, gastroenterological, psychiatric, respiratory diseases, as well as severe hospital infections. In total, the volume of full-cycle production of drugs will amount to 16 million packages per year. The production, located in the Kaluga region, will comply with all international quality standards (GMP). "AstraZeneca will be the first of the Big Pharma companies to start construction of a full–cycle pharmaceutical production in Russia from scratch," the message says. As noted by the president of AstraZeneca Russia, Nenad Pavletic, whose comment is also given in the press release, in addition to localization of production, the company is going to invest in research and development. "Our immediate plans include a project to support Russian innovative developments in the field of fundamental science," he adds.
AstraZeneca Plc, one of the largest pharmaceutical companies in the world, was formed by the merger in 1999 of the British Zeneca Group Plc and the Swedish Astra AB. The company is engaged in the development, production and sale of drugs for the treatment of diseases of the gastrointestinal tract, cardiovascular, neurological, as well as oncological. AstraZeneca operates in more than 100 countries around the world and spends about four billion dollars a year on research and development. The company is headquartered in London. The total number of employees exceeds 62 thousand people, while more than 11 thousand are employed in the field of scientific research. The company's revenue for 2010 increased by 1.4% to $ 33.27 billion. In Russia, AstraZeneca is represented in 65 cities, while more than 30 of the company's original drugs are registered and allowed to be used in the country. Since 2007, AstraZeneca has been among the TOP 15 largest pharmaceutical companies in Russia with an annual turnover of about 200 million US dollars.
Portal "Eternal youth" http://vechnayamolodost.ru18.02.2011